


BPH-1358

| | |
|--------------------|--|
| Cat. No.: | HY-118946 |
| CAS No.: | 5352-53-4 |
| Molecular Formula: | C ₃₂ H ₃₀ Cl ₂ N ₆ O ₂ |
| Molecular Weight: | 601.53 |
| Target: | Bacterial |
| Pathway: | Anti-infection |
| Storage: | 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |



SOLVENT & SOLUBILITY

| | | | | | |
|---|--|--------------------------|-----------|-----------|------------|
| In Vitro | DMSO : 6.25 mg/mL (10.39 mM); ultrasonic and warming and heat to 60°C | | | | |
| | | Solvent Concentration | Mass | | |
| | Preparing Stock Solutions | | 1 mg | 5 mg | 10 mg |
| | | 1 mM | 1.6624 mL | 8.3121 mL | 16.6243 mL |
| 5 mM | | 0.3325 mL | 1.6624 mL | 3.3249 mL | |
| | 10 mM | 0.1662 mL | 0.8312 mL | 1.6624 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.62 mg/mL (1.03 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.62 mg/mL (1.03 mM); Clear solution | | | | |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|--|
| Description | BPH-1358 (NSC50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC ₅₀ s of 1.8 μM and 110 nM, respectively, and is active against <i>S. aureus</i> in vitro (MIC ~250 ng/mL) ^{[1][2]} . |
| IC ₅₀ & Target | IC ₅₀ : 1.8 μM (human bisphosphonate farnesyl diphosphate synthase) ^[1] ; 100 nM (undecaprenyl diphosphate synthase) ^[2] |
| In Vitro | BPH-1358 is the most potent inhibitor of both <i>E. coli</i> UPPS (EcUPPS) as well as <i>S. aureus</i> UPPS (SaUPPS) with an IC ₅₀ of 110 nM. BPH-1358 against <i>E. coli</i> and <i>S. aureus</i> with EC ₅₀ of 300 nM and 290 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | BPH-1358 is active against <i>S. aureus</i> in vivo (20/20 mice survived in an i.p. infection model with a MRSA strain) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Liu YL, et al. Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. *ACS Med Chem Lett.* 2015 Jan 29;6(3):349-54.
- [2]. Zhu W, et al. Antibacterial drug leads: DNA and enzyme multitargeting. *J Med Chem.* 2015 Feb 12;58(3):1215-27.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA